drugset / Trial / NCT00628433
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential activity of an investigational agent, HE3286, when administered orally, daily for 28 days to patients with mild-to-moderate ulcerative colitis.
Timeline
- Start
- 2008-02
- Primary completion
- 2009-05
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bezisterim | Small molecule | 4 mg | Oral |
| Subject | bezisterim | Small molecule | 5 mg | Oral |
| Subject | bezisterim | Small molecule | 10 mg | Oral |
| Subject | bezisterim | Small molecule | 20 mg | Oral |